A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5570 participants.

Also called NCT01709305

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,570 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01709305
Other papers using this trial's data
  • Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial Science China. Life sciences, 2017-03 DOI, PubMed 28271251

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01709305. Randomized; no masking; primary purpose treatment. Start 2012-11-08 (actual); primary completion 2015-04-17 (actual). Results posted on 2016-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Metformin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Acarbose
Intervention (Drug)
Repaglinide
Intervention (Drug)
Glimepiride
Intervention (Drug)
Gliclazide
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01709305
Content hash
220ad1ba3c4378e19a8800caedd1310fd0fe6b0b36dbcdee45d5f39c43e3aeec